March 5, 2019 / 7:47 AM / 4 months ago

BRIEF-Novartis touts Cosentyx over Johnson & Johnson's Stelara in psoriasis drug fight

March 5 (Reuters) - Novartis AG SAYS:

* NOVARTIS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS' QUALITY OF LIFE VERSUS JOHNSON & JOHNSON UNIT JANSSEN'S IL-23 STELARA

* NOVARTIS SAYS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS' QUALITY OF LIFE VERSUS JANSSEN'S IL-23 STELARA

* IN ADDITION, NEW PROSE STUDY DATA PRESENTED AS A LATE-BREAKER SUPPORTING BENEFIT OF COSENTYX TO IMPROVE PATIENT QOL

* COSENTYX CONTINUES TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE

* J&J PREVIOUSLY PUBLISHED STUDY SHOWING STELARA BEAT COSENTYX Source text for Eikon: [bit.ly/2EM3CS3] Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below